DaVita Inc. Common Stock (DVA): valor razonable

Tesis ACCE

DaVita runs outpatient dialysis clinics for patients with chronic kidney failure, and it also sells the lab and kidney-care services that surround them, so its revenue depends on treatment volume and reimbursement rather than on any single drug or device. Its moat is scale and density: a large clinic footprint in local markets, where dialysis patients are tied to nearby centers for three sessions a week, gives it referral relationships and cost leverage that smaller operators struggle to match. Revenue is growing about 5.2%, operating margin is 16.1%, and return on equity is 88.5%, which reflects a heavily leveraged balance sheet as much as operating quality, so the leverage deserves its own check. At roughly 10.6x forward earnings against 15.4x trailing, the market is pricing in earnings growth well above the current pace, which makes the next few quarters of margin and volume data the thing to verify before anything else. Our score is 76/100 and the stock is in no major index, a combination that may warrant a closer look at the cash flow and debt profile.